Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury
Tomohisa Nagoshi, … , Hunter C. Champion, Anthony Rosenzweig
Tomohisa Nagoshi, … , Hunter C. Champion, Anthony Rosenzweig
Published August 1, 2005
Citation Information: J Clin Invest. 2005;115(8):2128-2138. https://doi.org/10.1172/JCI23073.
View: Text | PDF | Corrigendum
Research Article Cardiology

PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury

  • Text
  • PDF
Abstract

Acute activation of the serine-threonine kinase Akt is cardioprotective and reduces both infarction and dysfunction after ischemia/reperfusion injury (IRI). However, less is known about the chronic effects of Akt activation in the heart, and, paradoxically, Akt is activated in samples from patients with chronic heart failure. We generated Tg mice with cardiac-specific expression of either activated (myristoylated [myr]) or dominant-negative (dn) Akt and assessed their response to IRI in an ex vivo model. While dn-Akt hearts demonstrated a moderate reduction in functional recovery after IRI, no function was restored in any of the myr-Akt–Tg hearts. Moreover, infarcts were dramatically larger in myr-Akt–Tg hearts. Biochemical analyses demonstrated that chronic Akt activation induces feedback inhibition of PI3K activity through both proteasome-dependent degradation of insulin receptor substrate–1 (IRS-1) and inhibition of transcription of IRS-1 as well as that of IRS-2. To test the functional significance of these signaling changes, we performed in vivo cardiac gene transfer with constitutively active PI3K in myr-Akt–Tg mice. Restoration of PI3K rescued function and reduced injury after IRI. These data demonstrate that PI3K-dependent but Akt-independent effectors are required for full cardioprotection and suggest a mechanism by which chronic Akt activation can become maladaptive.

Authors

Tomohisa Nagoshi, Takashi Matsui, Takuma Aoyama, Annarosa Leri, Piero Anversa, Ling Li, Wataru Ogawa, Federica del Monte, Judith K. Gwathmey, Luanda Grazette, Brian Hemmings, David A. Kass, Hunter C. Champion, Anthony Rosenzweig

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
Ad.BD110 rescues cardiac function and reduces injury after ischemia/repe...
Ad.BD110 rescues cardiac function and reduces injury after ischemia/reperfusion. (A) Immunoblotting reveals the c-myc epitope incorporated into BD110 only in Ad.BD110-injected myr-Akt–Tg hearts. (B) After immunoprecipitation with anti-p110α antibody, PI3K activity was measured in immune complexes using the fluorescence polarization assay. Results are expressed as a ratio to the mean value for NTg hearts (NTg, n = 10; myr-Akt alone, n = 5; myr-Akt with Ad.BD110, n = 6). *P < 0.001 versus NTg or Ad.BD110-injected myr-Akt hearts. (C) LVDP profiles during ischemia/reperfusion in NTg (filled squares; n = 13), myr-Akt (open circles; n = 8), and myr-Akt with Ad.BD110 injection (filled circles; n = 7). #P < 0.001 versus NTg; *P < 0.001 and **P < 0.05 versus myr-Akt alone; †P < 0.01 and ‡P < 0.001 versus NTg. (D) Maximum LVDP recovery achieved (percent of baseline) after ischemia/reperfusion. ##P < 0.0001 versus NTg or Ad.BD110-injected myr-Akt; §P < 0.02 versus NTg. (E) CPK activity in the effluent (NTg, n = 7; myr-Akt, n = 5; myr-Akt with Ad.BD110, n = 4). (F) Cardiac lysates were immunoblotted for IRS-1 expression. Actin was included as a loading control. (G) Cardiac lysates were analyzed for Akt kinase activity with GSK3α/β as substrate. Lysates from the same heart tissues were subjected to immunoblotting of phospho- and total GSK3.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts